Rachel Zebo

Bristol-Myers Squibb (Germany) — Germany

Medicine · Health Sciences

7h-index176citations9works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic function and diabetes(4), Hormonal Regulation and Hypertension(4), Pharmacogenetics and Drug Metabolism(2), Diabetes Treatment and Management(2), Peroxisome Proliferator-Activated Receptors(2)

Publications9 total

Discovery of liver-selective glucokinase activators comprising N-(4-alkylthiazol-2-yl)benzamides and N-(3-alkyl-1,2,4-thiadiazol-5-yl)benzamides for the treatment of metabolic disorders
Bioorganic & Medicinal Chemistry Letters·2025
Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1<i>H</i>-pyrazol-1-yl)methyl)phosphonate (BMS-820132)
Journal of Medicinal Chemistry·2022· 9 citedOpen Access
Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)
ACS Medicinal Chemistry Letters·2018· 5 citedOpen Access
Discovery of Clinical Candidate 2-((2<i>S</i>,6<i>S</i>)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3′-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor
Journal of Medicinal Chemistry·2017· 14 citedOpen Access
Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1<i>H</i>)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119
Journal of Medicinal Chemistry·2014· 45 citedOpen Access
Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)
ACS Medicinal Chemistry Letters·2014· 22 citedOpen Access
Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1)
Bioorganic & Medicinal Chemistry Letters·2011· 27 citedOpen Access
Discovery of azetidinone acids as conformationally-constrained dual PPARα/γ agonists
Bioorganic & Medicinal Chemistry Letters·2008· 37 citedOpen Access
The Dual Peroxisome Proliferator-Activated Receptor α/γ Activator Muraglitazar Prevents the Natural Progression of Diabetes in db/db Mice
Journal of Pharmacology and Experimental Therapeutics·2007· 17 cited

Frequent Co-authors

Randolph Ponticiello(6), Jeffrey A. Robl(6), Thomas Harrity(6), Joseph R. Taylor(6), Nathan Morgan(5), Zhenqiu Hong(4), Lori Kunselman(4), Peter T. W. Cheng(4), Shung Wu(4), David Yoon(4), Ramakrishna Seethala(4), Rajasree Golla(4), Timothy W. Harper(4), Akbar Nayeem(4), S. Sheriff(4), Daniel M. Camac(4), Paul E. Morin(4), Jacob Zalaznick(3), Bradley A. Zinker(3), Jun Li(3)